CYP4F12 and neoplasm: Since overexpression of CYP4F12 is involved in inhibition of tumor progression and metastasis and its low expression has been associated with poor patient survival [45]; increased expression of CYP4F12 in the combination therapy demonstrates its therapeutic advantage.